Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Comparison of nevirapine plasma concentrations between lead-in and steady-state periods in Chinese HIV-infected patients.

Kou H, Du X, Li Y, Xie J, Qiu Z, Ye M, Fu Q, Han Y, Zhu Z, Li T.

PLoS One. 2013;8(1):e52950. doi: 10.1371/journal.pone.0052950.

2.

The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals.

van Heeswijk RP, Veldkamp AI, Mulder JW, Meenhorst PL, Wit FW, Lange JM, Danner SA, Foudraine NA, Kwakkelstein MO, Reiss P, Beijnen JH, Hoetelmans RM.

AIDS. 2000 May 26;14(8):F77-82.

PMID:
10853971
3.

Pharmacokinetics of nevirapine: once-daily versus twice-daily dosing in the 2NN study.

Kappelhoff BS, Huitema AD, van Leth F, Robinson PA, MacGregor TR, Lange JM, Beijnen JH; 2NN Study Group..

HIV Clin Trials. 2005 Sep-Oct;6(5):254-61.

PMID:
16306032
4.

The relationship between nevirapine plasma concentrations and abnormal liver function tests.

Almond LM, Boffito M, Hoggard PG, Bonora S, Raiteri R, Reynolds HE, Garazzino S, Sinicco A, Khoo SH, Back DJ, Di Perri G.

AIDS Res Hum Retroviruses. 2004 Jul;20(7):716-22.

PMID:
15307917
5.

Trough concentrations of lopinavir, nelfinavir, and nevirapine with standard dosing in human immunodeficiency virus-infected pregnant women receiving 3-drug combination regimens.

Baroncelli S, Villani P, Floridia M, Pirillo MF, Galluzzo CM, Cusato M, Amici R, Pinnetti C, Sabbatini F, Molinari A, Tamburrini E, Regazzi M.

Ther Drug Monit. 2008 Oct;30(5):604-10. doi: 10.1097/FTD.0b013e3181867a6e.

PMID:
18728627
6.

Nevirapine plasma concentrations are associated with virologic response and hepatotoxicity in Chinese patients with HIV infection.

Wang J, Kou H, Fu Q, Han Y, Qiu Z, Zuo L, Li Y, Zhu Z, Ye M, Ma Q, Li T.

PLoS One. 2011;6(10):e26739. doi: 10.1371/journal.pone.0026739.

7.

[Efavirenz and nevirapine plasma levels in HIV-infected patients with hemophilia].

Martorell M, López RM, Ribera E, Ruiz I, Tural C, Puig L, Monterde J.

Enferm Infecc Microbiol Clin. 2005 Jun-Jul;23(6):349-52. Spanish.

PMID:
15970167
8.

Increasing nevirapine dose can overcome reduced bioavailability due to rifampicin coadministration.

Ramachandran G, Hemanthkumar AK, Rajasekaran S, Padmapriyadarsini C, Narendran G, Sukumar B, Sathishnarayan S, Raja K, Kumaraswami V, Swaminathan S.

J Acquir Immune Defic Syndr. 2006 May;42(1):36-41.

PMID:
16639340
9.

Nevirapine concentrations in HIV-infected children treated with divided fixed-dose combination antiretroviral tablets in Malawi and Zambia.

Ellis JC, L'homme RF, Ewings FM, Mulenga V, Bell F, Chileshe R, Molyneux E, Abernethy J, van Oosterhout JJ, Chintu C, Walker AS, Gibb DM, Burger DM.

Antivir Ther. 2007;12(2):253-60.

PMID:
17503667
10.

Cytochrome P450 2B6 516G-->T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population.

Mahungu T, Smith C, Turner F, Egan D, Youle M, Johnson M, Khoo S, Back Dj, Owen A.

HIV Med. 2009 May;10(5):310-7. doi: 10.1111/j.1468-1293.2008.00689.x. Erratum in: HIV Med. 2009 Nov;10(10):661.

11.

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Cvetkovic RS, Goa KL.

Drugs. 2003;63(8):769-802. Review.

PMID:
12662125
12.

Lipid-based nutrient supplements do not affect efavirenz but lower plasma nevirapine concentrations in Ethiopian adult HIV patients.

Abdissa A, Olsen MF, Yilma D, Tesfaye M, Girma T, Christiansen M, Hagen CM, Wiesner L, Castel S, Aseffa A, McIlleron H, Pedersen C, Friis H, Andersen AB.

HIV Med. 2015 Aug;16(7):403-11. doi: 10.1111/hiv.12225.

PMID:
25974723
13.

Once- or twice-daily dosing of nevirapine in HIV-infected adults: a population pharmacokinetics approach.

Moltó J, Valle M, Miranda C, Cedeño S, Miranda J, Santos JR, Negredo E, Vilaró J, Costa J, Clotet B.

J Antimicrob Chemother. 2008 Oct;62(4):784-92. doi: 10.1093/jac/dkn268.

14.

Changes in nevirapine plasma concentrations over time and its relationship with liver enzyme elevations.

De Requena DG, Jiménez-Nácher I, Soriano V.

AIDS Res Hum Retroviruses. 2005 Jun;21(6):555-9.

PMID:
15989460
15.

Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study.

Kappelhoff BS, van Leth F, MacGregor TR, Lange J, Beijnen JH, Huitema AD; 2NN Study Group..

Antivir Ther. 2005;10(1):145-55.

PMID:
15751772
16.

Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda.

Penzak SR, Kabuye G, Mugyenyi P, Mbamanya F, Natarajan V, Alfaro RM, Kityo C, Formentini E, Masur H.

HIV Med. 2007 Mar;8(2):86-91.

17.

Factors influencing plasma nevirapine levels: a study in HIV-infected children on generic antiretroviral treatment in India.

Swaminathan S, Ramachandran G, Agibothu Kupparam HK, Mahalingam V, Soundararajan L, Perumal Kannabiran B, Navaneethapandian PG, Shah I, Karunaianandham R, Sikhamani R.

J Antimicrob Chemother. 2011 Jun;66(6):1354-9. doi: 10.1093/jac/dkr075.

18.

Lack of association between plasma levels of non-nucleoside reverse transcriptase inhibitors & virological outcomes during rifampicin co-administration in HIV-infected TB patients.

Ramachandran G, Kumar AK, Ponnuraja C, Ramesh K, Rajesh L, Chandrasekharan C, Swaminathan S.

Indian J Med Res. 2013 Dec;138(6):955-61.

19.

Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population.

de Vries-Sluijs TE, Dieleman JP, Arts D, Huitema AD, Beijnen JH, Schutten M, van der Ende ME.

Clin Pharmacokinet. 2003;42(6):599-605.

PMID:
12793844
20.

Steady-state pharmacokinetics of lamivudine once-daily versus twice-daily dosing in Chinese HIV-infected patients.

Ye M, Wang L, Fu Q, Zhu Z, Li P, Li T.

HIV Clin Trials. 2010 Jul-Aug;11(4):230-7. doi: 10.1310/hct1104-230.

PMID:
20974578
Items per page

Supplemental Content

Support Center